CASP3 and cancer: Our time-course study revealed that C3 labeled cancer cells is more powerful in time-lapse evaluation of drug efficacy than conventional antibody-based caspase-3 activation assay or apoptosis staining approaches (such as TUNEL assay), which only monitor the endpoint and unable to detect early drug response of the culture.